Loading clinical trials...

Sequent Extended Study | Clinical Trials | Clareo Health

RECRUITING

Sequent Extended Study

Sequent Please Neo Extended Post-Market Clinical Follow-up Study

NCT05788432•Fundación EPIC

Summary

Multicenter, prospective, non-randomized, post-market clinical follow-up (PMCF) study to confirm and support the clinical safety and performance of Sequent Please Neo to meet EU Medical Device regulation (MDR) requirements in all the consecutive patients treated with Sequent Please Neo.

Detailed Description

The objective of this multicenter, prospective, non-randomized, postmarket clinical follow-up(PMCF) study is to confirm and support the clinical safety and performance of the Sequent Please Neo in a NON-SELECTED, Real Word population under daily clinical practice when used as intended by the manufacturer to meet EU Medical Device Regulation requirements for post-market clinical follow-up.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients treated with Sequent please neo according to routine hospital practice and following instruction for use.
•Informed Consent Signed.

Exclusion Criteria

•Patient life expectancy less than 12 months.
•Contraindication for antiplatelet therapy.

Locations (26)

Hospital Universitario de Araba

Alava, Spain

Hospital General Universitario de Alicante Dr.Balmis

Alicante, Spain

Hospital Universitario de Badajoz

Badajoz, Spain

Hospital Universitari Germans Trias I Pujol

Badalona, Spain

Hospital Universitario de Cruces

Barakaldo, Spain

Hospital de La Santa Creu Y Sant Pau

Barcelona, Spain

Hospital Clinic de Barcelona

Barcelona, Spain

Hospital Universitario Puerta Del Mar

Cadiz, Spain

Hospital General Universitari de Castelló

Castelló, Spain

Hospital Universitario San Pedro de Alcantara

Cáceres, Spain

Key Dates

Start Date

March 28, 2023

Primary Completion Date

June 1, 2026

Completion Date

July 1, 2026

Last Updated

February 3, 2026

Enrollment

2,028

ESTIMATED participants

Conditions

Coronary Artery DiseaseIschemic Heart Disease

Interventions

Sequent Please Neo

DEVICE

Contacts

ORIOL RODRIGUEZ LEOR, MD, PhD

CONTACT

0034934651200 oriolrodriguez@gmail.com

FUNDACION EPIC

CONTACT

0034987876135 iepic@fundacionepic.org

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

NCT05681702

Coronary Artery Disease

View study

RECRUITING

"Erectile Function After PCI in MI and Non-MI Patients"

NCT07444697

Erectile DisfunctionCoronary Artery Disease (CAD)+3 more

View study

RECRUITING

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 3, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Sequent Extended Study

Inclusion Criteria

Exclusion Criteria

Tailoring Bleeding Reduction Approaches in Patients Undergoing PCI

"Erectile Function After PCI in MI and Non-MI Patients"

Revascularization Strategies in Patients With Non-ST-Segment Elevation Acute Coronary Syndrome (NSTE-ACS) and Severe Coronary Artery Disease

Product Surveillance Registry

Essential Pro Study ( rEPIC04E-HK )

Factors Affect Outcomes in Cardiovascular Surgery